Clinical trial NCT01616290: Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)
Official title: Open-Label, Dose-Escalation, Pilot Study of PRT-201 Administered Following Angioplasty in Patients With Peripheral Artery Disease in the Lower Extremity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Peripheral Artery Disease
Keywords: peripheral artery disease
PAD
claudication
angioplasty
percutaneous transluminal angioplasty
PTA
superficial femoral artery
SFA
popliteal artery
PA
PRT-201
restenosis
vonapanitase
Lead sponsor: Proteon Therapeutics
Sponsor class: INDUSTRY
Collaborators: name: University of California, San Francisco
First posted: 2012-06-11
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if it is safe and feasible to apply PRT-201 to the adventitia of arteries following successful angioplasty (PTA).


Eligibility criteria: Inclusion Criteria:

1. Age of at least 18 years
2. Clinical diagnosis of PAD, secondary to atherosclerosis affecting a lower limb
3. Rutherford classification 2-4 (moderate claudication to ischemic rest pain)
4. ABI \<0.90 at rest or with exercise, or a toe-brachial index \<0.70, or radiographic evidence of PAD that correlates with clinical symptoms
5. De novo lesion, not previously treated by angioplasty or atherectomy
6. Greater than 70% stenosis of the SFA or PA, target lesion length of 10 cm or less, and at least one patent runoff vessel. Short segment occlusions (\<10 cm) are acceptable
7. If female and of childbearing potential (premenopausal and not surgically sterile) must have a negative pregnancy test at the screening visit and be willing to use contraception from the time of the screening visit to 1 week following study drug administration. Acceptable methods of birth control include abstinence, barrier methods with spermicide, implants, injectables, oral contraceptives, intra-uterine device, or a vasectomized partner
8. Ability to understand and comply with the requirements of the entire study and communicate with the study team
9. Ability to provide written informed consent using a document that has been approved by the required institutional review board

Exclusion Criteria:

1. Previous treatment with PRT-201
2. Patients in whom arterial insufficiency in the lower extremity is the result of an immunologic or inflammatory non-atherosclerotic disorder (e.g. Buerger's disease, vasculitis)
3. Current severe critical limb ischemia defined as ulceration or gangrene
4. Planned atherectomy of the arteries of the index leg
5. Prior or planned stenting of the target lesion
6. Prior bypass surgery to the target SFA or PA
7. Severe concentric medial calcification of the target lesion thought to interfere with drug delivery to the adventitia that is defined subjectively by the Investigator based on fluoroscopic appearance.
8. History of metastatic cancer
9. Presence of aortic or peripheral artery aneurysm
10. Platelet count \<130K, hematocrit \<30%, bilirubin or ALT \>3.0 times the upper limit of normal
11. Pregnancy, lactation or plans to become pregnant during the course of the study
12. Presence of any significant medical condition that might significantly confound the collection of safety and efficacy data in this study
13. Treatment with any investigational drug within the previous 30 days or investigational antibody therapy within 90 days prior to signing informed consent
14. Known allergy to contrast media

Primary outcomes:
measure: Clinical Safety
timeFrame: 12 months following PTA and study drug administration
Secondary outcomes:
measure: Technical success of adventitial administration of PRT-201
timeFrame: Immediately following study drug administration
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: San Francisco VA Medical Center
state: California
city: San Francisco
country: United States
facility: University of California, San Francisco Medical Center
state: California
Study officials:
affiliation: San Francisco VA Medical Center
name: Christopher D Owens, M.D., M.Sc
role: PRINCIPAL_INVESTIGATOR
References: